We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

3-year Immunogenicity Evaluation of Quadrivalent HPV Vaccine in China

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2011 by Rongcheng Li, Guangxi Center for Disease Control and Prevention.
Recruitment status was:  Not yet recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01427777
First Posted: September 2, 2011
Last Update Posted: September 2, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Rongcheng Li, Guangxi Center for Disease Control and Prevention
September 1, 2011
September 2, 2011
September 2, 2011
September 2011
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
3-year Immunogenicity Evaluation of Quadrivalent HPV Vaccine in China
The Thirty-six-Month Immunogenicity Evaluation of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Chinese Female Subjects Aged 9 to 45 Years and Male Subjects Aged 9 to 15 Years
The thirty-six-month immunogenicity evaluation of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Chinese female subjects aged 9 to 45 years and male subjects aged 9 to 15 years.
All eligible subjects will be enrolled for one visit. A medical history and physical examination will be conducted on all subjects. A 10 mL blood specimen will be collected. All Sera should be shipped to PPD Vaccines and Biologics Laboratory in the US. The serum specimen will be tested at PPD Laboratory with competitive Luminex immunoassay (cLIA) and multiplexed HPV immunoassay. The purpose of the quadrivalent HPV cLIA and multiplex is to detect neutralizing antibody and total IgG to HPV virus-like particles (VLPs), serotypes 6, 11, 16, 18, respectively.
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Subjects who participated in V501-030 in Per-protocol population
Anogenital Human Papilloma Virus Infection
Not Provided
HPV Vaccine
People that receive HPV vaccine in V501-030
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
300
June 2012
Not Provided

Inclusion Criteria:

  • Healthy Chinese subject who participated in V501-030 in Per-protocol population.
  • Subject agrees to provide study personnel with a primary telephone number as well as an alternate telephone number for follow-up purposes.
  • Subject is willing to give consent/assent.

Exclusion Criteria:

  • Subject is concurrently enrolled in clinical studies of investigational agents which may interfere with the evaluation of the study objectives.
  • Subject has any condition which in the opinion of the investigator might interfere with the evaluation of the study objectives
  • Subject has a history of known prior vaccination with a HPV vaccine, either active agent or placebo after receiving the vaccination during V501-030
Sexes Eligible for Study: All
9 Years to 45 Years   (Child, Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
China
 
 
NCT01427777
V501-030-1
No
Not Provided
Not Provided
Rongcheng Li, Guangxi Center for Disease Control and Prevention
Guangxi Center for Disease Control and Prevention
Not Provided
Principal Investigator: Rongcheng Li, MD Guangxi CDC
Guangxi Center for Disease Control and Prevention
September 2011